7 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
business; and the impact of the COVID-19 pandemic, the Russian invasion of Ukraine
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
on BioLineRx's business; the impact of any resurgence of the COVID-19 pandemic, the Russian invasion
7hcyjbfxxr0aevm3czfj1m6oq78e9fnodpv0ldyi
BLRX
17 Apr 24
in Israel on BioLineRx's business; the impact of any resurgence of the COVID-19 pandemic, the Russian
dcwiv5380zptvxytflta12wol2dzwtl9142s5rizj04cwnj4fmo
BLRX
4 Mar 24
in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian
- Prev
- 1
- Next